1 - 10 (out of 21)
rAAV.MRTF-A-based vascular gene therapy in chronic hindlimb ischemia
Peripheral artery disease is a disabling and prognostically unfavorable condition, caused by impairment of lower limb perfusion.
| Principal Investigators | Christian Kupatt (Klinikum rechts der Isar der Technischen Universität München) |
|---|---|
| Project status | running |
Generation and functional characterisation of macrophage cell lines from yolk sac precursors
The tissue macrophages in adult organs, including those of the cardiovascular system, mostly originate from embryonic precursors located in the yolk-sac. However, existing macrophage cell lines mostly derive from peripheral blood mononuclear cells or leukemic cells.
| Principal Investigators | Christian Schulz (Hospital of Ludwig Maximilian University of Munich) |
|---|---|
| Project status | completed |
Late pre-clinical development of CD40-TRAF6 inhibitors (TRAF-STOPs)
Blocking the co-stimulatory CD40L-CD40 dyad reduces atherosclerosis. We found that the interaction between CD40 and TNF-receptor-associated factor 6 (TRAF6) is the driving force for atherosclerosis.
| Principal Investigators | Christian Weber, Esther Lutgens, Dorothee Atzler (University Hospital of Munich) |
|---|---|
| Project status | completed |
Real-time MRI-guided targeted endomyocardial biopsy of radiofrequency-induced lesions in pigs
The diagnostic benefit of catheter-assisted endocardial myocardial biopsy under fluoroscopy control is mainly limited due to sampling errors.
| Principal Investigators | Christina Unterberg-Buchwald (University Medical Centre Göttingen) |
|---|---|
| Project status | running |
Re-screening for novel CD40-TRAF6 interaction inhibitors (TRAF-STOPs 2.0)
In this project, we aim to screen for new small molecule inhibitors, which can specifically block the inflammatory signals contributing to atherosclerosis as the dominating cause underlying cardiovascular disease, and may therefore serve as potential drug candidates for anti-inflammatory treatment.
| Principal Investigators | Dorothee Atzler, Christian Weber, Esther Lutgens (Hospital of Ludwig Maximilian University of Munich) |
|---|---|
| Project status | running |
Transapical mitral-valve stent implantation without using a heart-lung machine
The object of this project is the therapy of mitral-valve insufficiency by means of a transapical mi-tral-valve stent implantation in the beating heart without using a heart-lung machine.
| Principal Investigators | Georg Lutter (Kiel University Christian-Albrechts-Universität zu Kiel) |
|---|---|
| Project status | completed |
Hit-to-lead development of CaMKII-HDAC4 inhibitory compounds to treat heart failure (project 1: Identification of potent hits)
The two proteins calcium/calmodulin-dependent protein kinase II (CaMKII) and histone deacetylase 4 (HDAC4) are formed in the heart. These play essential roles in maintaining the heart's function, but also in the development of diseases.
| Principal Investigators | Johannes Backs (University Hospital Heidelberg) |
|---|---|
| Project status | completed |
Local miR-29b inhibition using drug eluting balloons to block abdominal aortic aneurysm progression
An abdominal aortic aneurysm, which is a vascular “ballooning” of the aorta in the abdomen, is caused by a weak vascular wall. If an aneurysm ruptures, it's often fatal.
| Principal Investigators | Lars Maegdefessel (Klinikum rechts der Isar der Technischen Universität München) |
|---|---|
| Project status | running |
Gene therapy for neonatal sarcomeric cardiomyopathies: towards first-in-patient
One of the most frequent causes of cardiomyopathy in newborns are homozygous or complex heterozygous mutations of the MYBPC3 gene which encodes the cardiac myosin-binding protein C, a protein belonging to the sarcomere.
| Principal Investigators | Lucie Carrier (University Hospital Hamburg-Eppendorf) |
|---|---|
| Project status | completed |
In vivo characterisation of the chemokine recep-tor CXCR4 to detect an inflammation in athero-sclerotic plaques by means of PET/MR
It was demonstrated in preliminary studies with animal atherosclerosis models that the radionuclide 68Ga-Pentixafor binds specifically to cells which mediate an inflammation process and thus enables a non-invasive assessment of an inflammation in atherosclerotic plaques.
| Principal Investigators | Markus Schwaiger (Klinikum rechts der Isar der Technischen Universität München) |
|---|---|
| Project status | completed |